PALO ALTO, Calif., Oct. 22 -- TOPICA Pharmaceuticals today announced that Greg Vontz, presidentand CEO, will present at the following investor conferences next week:
During the presentations, Mr. Vontz will provide an overview of TOPICA and its clinical development progress and plans for luliconazole, one of the most potent and broad spectrum topical antifungal agents, for the treatment of tinea pedis (athlete's foot) and onychomycosis (fungal infections of the nail).
About TOPICA Pharmaceuticals
TOPICA is a privately-held specialty pharmaceutical company focused on licensing, developing and commercializing potent topical prescription products to treat the needs of patients with serious nail and skin conditions. Taking advantage of its established trans-pacific network of scientific and industry contacts, TOPICA has in-licensed its lead product candidate, luliconazole, a topical antifungal agent that is already on the market in Japan. TOPICA is developing luliconazole for the treatment of tinea pedis (athlete's foot) and onychomycosis (fungal infections of the nail). For more information, please visit http://www.topicapharma.com.
SOURCE TOPICA Pharmaceuticals
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All